Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients

Bibliography

• Guidelines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007;16:135-232
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• Erdine S. How well is hypertension controlled in Europe? J Hypertens 2000;18:1348-9
   Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H, Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17
   PubMed Web of Science ®Google Scholar
• Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001;14:241-7
   PubMed Web of Science ®Google Scholar
• Dickerson JE, Hingorani AD, Ashby MJ, Optimisation of antihypertensive treatment bycrossover rotation of four major classes. Lancet 1999;353:2008-13
   PubMed Web of Science ®Google Scholar
• WHO, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-92
   PubMed Web of Science ®Google Scholar
• Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002;62:1345-53
   PubMed Web of Science ®Google Scholar
• Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens Suppl 2003;21:43-6
   Google Scholar
• Chilman-Blair K, Rabesseda X. Olmesartan, an AT1-selective antihypertensive agent. Drugs Today 2003;39:745-61
   PubMed Web of Science ®Google Scholar
• Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens Suppl 2001;19:49-56
   PubMedGoogle Scholar
• Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004;26:28-32
   PubMed Web of Science ®Google Scholar
• Oparil S, Williams D, Chrysant SG, Comparative efficacy of olmesartan, losartan, valsartan and Irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-91
   PubMedGoogle Scholar
• Bergmann K, Laeis P, Puchler K, Olmesartan medoxomil influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001;19:33-40
   Google Scholar
• Laeis P, Pucher K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens 2001;19:21-32
   PubMed Web of Science ®Google Scholar
• Puchler K, Laeis P, Stumpe K. Blood pressure response, but not adverse event incidence, correlates with dose of Angiotensin II antagonist. J Hypertens 2001;19:41-8
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252-9
   PubMed Web of Science ®Google Scholar
• Oparil S, Chrysant SG, Kereiakes D, Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens 2008;10:911-21
   PubMed Web of Science ®Google Scholar
• Roger VL. Cardiovascular disease surveillance in the comparative effectiveness landscape. Circ Cardiovasc Qual Outcomes 2009;2:404-6
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. Available from: http://www.kidney.org/kidneydisease/ckd/knowgfr.cfm#chart [Accessed 18th May 2010]
   Google Scholar
• Vandenbroucke JP, von Elm E, Altman DG, Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Gac Sanit 2007;18:805-35
   Google Scholar
• Yusuf S, Teo KK, Pogue J, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326(7404):1427
   PubMed Web of Science ®Google Scholar
• White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 2007;49:408-18
   PubMed Web of Science ®Google Scholar
• Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol 2006;1:229-35
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA, Weir MR, Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18:308-47
   PubMed Web of Science ®Google Scholar
• Sellin L, Stegbauer J, Laeis P, Rump LC. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005;23:2083-92
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderon A, Bohm M. Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study. Vasc Health Risk Manag 2009;5:723-9
   PubMedGoogle Scholar
• Wald DS, Law M, Morris JK, Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
   PubMed Web of Science ®Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407
   PubMed Web of Science ®Google Scholar
• Brown MJ. Renin: friend or foe? Heart 2007;93:1026-33
   PubMed Web of Science ®Google Scholar
• Destro M, Cagnoni F, D'Ospina A, Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update. Vasc Health Risk Manag 2010;6:253-60
   PubMedGoogle Scholar
• Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vasc Health Risk Manag 2008;4:653-64
   PubMedGoogle Scholar